Quest and Hemispherx partnered to evaluate Quest's cancer candidate oregovomab with Hemispherx's Ampligen rintatolimod

Quest PharmaTech Inc.

Canada / Small-Cap Biopharma (<$1 billion)

Other

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Hemispherx Biopharma Inc.

U.S. / Small-Cap Biopharma (<$1 billion)

Other

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced